

Summary of Changes – 2/2/2026

Tretinoins (Topical) PA 237-A 08-2025 v2 - Removed brand Veltin from target drug list (product no longer available). Generic remains targeted.

IVIG SGM 2042-A 2025 - Added PANS/PANDAS and central nervous system-predominant retinocochleocerebral vasculopathy as compendial uses. Added Gammagard Liquid ERC and Qivigy to policy.

SCIG SGM 2043-A 2025 - Added PANS/PANDAS and central nervous system-predominant retinocochleocerebral vasculopathy as compendial uses.

GamaSTAN SGM 2067-A 2025 - Removed criteria “Member was exposed to varicella within the past 10 days and Member is at high risk for severe varicella (e.g., immunocompromised persons, newborns/infants, pregnant women)” from prophylaxis of varicella as no longer recommended in guideline.

Joenja SGM 5859-A 2025 - For initial, updated duration of approval from 6 month to 12 months.

Xolremdi SGM 6492-A 2025 - For initial, updated duration of approval from 6 month to 12 months.

Kevzara SGM 1957-A 2025 - For other section, updated TB testing requirement to be within 12 months of initiating therapy (previously was within 6 months of initiating therapy).

Orencia SGM 2127-A 2025 - For other section, updated TB testing requirement to be within 12 months of initiating therapy (previously was within 6 months of initiating therapy).

Simponi Aria SGM 2015-A 2025 - For other section, updated TB testing requirement to be within 12 months of initiating therapy (previously was within 6 months of initiating therapy).

Simponi SGM 2014-A 2025 - For ulcerative colitis, updated the FDA approved indications section to reflect the age expansion to pediatrics weighing 15 kilograms (kg) or more (previously approved in adults) per FDA label date.

Xeljanz-Xeljanz XR SGM 2011-A 2025a - For psoriatic arthritis, updated criteria to approve for pediatric patients 2 years of age and older per FDA label expansion (previously approved in adults).

Tavalisse SGM 2560-A 2025 - 1) Simplified diagnosis requirement from "chronic ITP" to "ITP". 2) Added "oncologist" as an additional option under prescriber specialties.

Prolia and Biosimilars SGM 2026-A 2024d - Added the new FDA-approved biosimilar of Prolia, Enoby (denosumab-qbde), to the criteria. The criteria remain clinically unchanged.

Xgeva and Biosimilars SGM 2152-A 2024d - Added the new FDA-approved biosimilar of Xgeva, Xtrenbo (denosumab-qbde), to the criteria. The criteria remain clinically unchanged.

Global Step Therapy Nebraska Mandate REG 4883-D 10-2025 - Removed brand/generic questions.

Rybrevant SGM 4745-A 2025a - Removed first line use requirement for treatment of non small cell lung cancer when used in combination with Lazcluze (lazertinib), per NCCN.

nilotinib products SGM 1793-A 2025a - Added Nilceya (nilotinib d-tartrate) to criteria.

Vitrakvi SGM 2799-A 2025 - Added coverage for histiocytic neoplasms per NCCN. Updated continuation of therapy criteria for NTRK positive gastrointestinal stromal tumor to only require no evidence of unacceptable toxicity per NCCN.

levoleucovorin-Khapzory SGM 1661-A 2025 - Removed discontinued brand Fusilev.

Rubraca SGM 2256-A 2025 - Removed requirement that prostate cancer has been treated with a taxane based chemotherapy or is not fit for chemotherapy to align with NCCN.

Caprelsa 1783-A SGM 2025 - Removed requirement that oncocytic thyroid carcinoma is not amenable to radioactive iodine therapy per NCCN.

Vyloy SGM 6703-A 2025 - Added esophageal adenocarcinoma as compendial use per NCCN. Added coverage for recurrent gastric and gastroesophageal junction adenocarcinoma per NCCN.

Tivdak SGM 4985-A 2025 - For cervical cancer, added coverage for use in combination with pembrolizumab.

Rozlytrek SGM 3165-A 2025 - Added coverage for histiocytic neoplasms per NCCN. Updated continuation of therapy criteria for NTRK positive gastrointestinal stromal tumor to only require no evidence of unacceptable toxicity per NCCN.

Augtyro SGM 6256-A 2025 - Added coverage for histiocytic neoplasms with NTRK gene fusion per NCCN. Updated continuation of therapy criteria for NTRK positive gastrointestinal stromal tumor to only require no evidence of unacceptable toxicity per NCCN.

Krazati SGM 5699-A 2025 - Added coverage for small bowel adenocarcinoma per NCCN.

Gavreto SGM 4206-A 2025 - Removed age requirement for follicular, papillary, and oncocytic thyroid carcinoma to align with NCCN. Added coverage for progressive/symptomatic follicular, papillary, and oncocytic thyroid carcinoma per NCCN. Removed requirement that oncytic thyroid carcinoma is not amenable to radioactive iodine therapy per NCCN.

cabazitaxel-Jevtana SGM 1932-A 2025 - Added coverage for metastatic castration-resistant small cell/neuroendocrine prostate cancer per NCCN.

Erbitux SGM 1892-A 2025 - Consolidated squamous cell carcinoma of the head and neck and occult primary head and neck cancer into head and neck cancer and added coverage for use in combination with chemotherapy per NCCN.

Danyelza SGM 4372-A 2025 - Added coverage for progressive disease per NCCN.

Brukinsa SGM 3411-A 2025_R - Added coverage for Primary CNS Lymphoma per NCCN

Calquence SGM 2397-A 2025 - For mantle cell lymphoma, added with or without bendamustine to use for combination with rituximab for induction therapy per NCCN. For chronic lymphocytic leukemia/small lymphocytic lymphoma, added criteria for combination use with venetoclax with or without obinutuzumab per NCCN.

Jaypirca 5767-A SGM 2025 - Updated Mantle Cell Lymphoma (MCL) coverage from third line to subsequent treatment if member has tried a covalent BTK inhibitor per NCCN

Copiktra SGM 2754-A 2025 - For T-cell lymphomas, added use in combination with romidepsin in when there is intention to proceed to transplant per NCCN.

Monjuvi 4056-A SGM 2025 - Added coverage for classic follicular lymphoma per NCCN and FDA label update. For diffuse large B-cell lymphoma, high-grade B-cell lymphoma, HIV-related B-cell lymphoma, and monomorphic PTLD removed requirement of not a transplant candidate per NCCN.

Aucatzy SGM 6730-A 2025 - Added coverage for lymphoblastic lymphoma per NCCN.

Eylea-Eylea HD and Biosimilars SGM 2024-A 2025b - Updated program to allow for approval of Eylea HD for macular edema following retinal vein occlusion (RVO) per recent label update.

New Guidelines

Inlexzo SGM 7229-A 2025 - Authorization of up to 12 months may be granted for the treatment of BCG-unresponsive, NMIBC with CIS, with or without papillary tumors when all of the following criteria are met:

1. The requested drug will be used as a single agent inserted intravesically.
2. The requested drug will be given once every 3 weeks for up to 6 months, followed by once every 12 weeks for up to 18 months.

Palsonify SGM 7223-A 2025 - Authorization of 12 months may be granted for the treatment of acromegaly when all of the following criteria are met: 1) Member has a high pretreatment IGF-1 level for age and/or gender based on the laboratory reference range 2) Member had an inadequate or partial response to surgery OR there is a clinical reason why the member has not had surgery.

Jascayd SGM 7235-A 2025 - Asking for prescriber specialty, diagnosis of idiopathic pulmonary fibrosis supported by diagnostic work. Continuation based on disease stability or improvement.

List of criteria that have completed the annual review process. No clinical changes.

- Adapalene PA with Limit 351-C 08-2025
- Compound Exception 1181-A 09-2025
- Emsam PA 867-A 07-2025
- Regranex PA with Limit 186-C 07-2025
- Adzynma SGM 6250-A 2025
- Cablivi SGM 2871-A 2025
- Enjaymo SGM 5189-A 2025
- Piasky SGM 6538-A 2025
- Veopoz SGM 6134-A 2025
- Voydeya SGM 6466-A 2025
- Ultomiris SGM 2835-A 2025a
- Soliris and Biosimilars SGM 3537-A 2025a
- Fabhalta SGM 6288-A 2025b
- Asparlas SGM 2833-A 2025
- Ayvakit SGM 3491-A 2025

- Fruzaqla 6246-A SGM 2025
- Iwilfin SGM 6294-A 2025
- Lonsurf SGM 1896-A 2025
- Lytgobi 5638-A SGM 2025
- Oncaspar 2291-A SGM 2025
- Pemazyre 3822-A SGM 2025
- Purixan SGM 2982-A 2025
- Qinlock SGM 3901-A 2025
- Rylaze 4812-A SGM 2025
- Tabrecta 3878-A SGM 2025
- Tepmetko 4492-A SGM 2025
- Zepzelca 3970-A SGM 2025
- Tecelra SGM 6580-A 2025
- Tukysa SGM 3782-A 2025a
- Vectibix SGM 2035-A 2025
- Xpovio SGM 3119-A 2025
- Xofigo 5717-A SGM 2025
- Zaltrap SGM 1667-A 2025
- Yonsa SGM 2596-A 2025
- Zevalin SGM 5754-A 2025
- Ziihera SGM 6735-A 2025
- Zydelig SGM 1706-A 2025